Engineered immune cells take on tough lung cancer in new trial
NCT ID NCT07564401
First seen May 09, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tests a new treatment called DJI136 for people with extensive-stage small cell lung cancer (ES-SCLC) that has worsened after standard therapy. DJI136 uses a patient's own immune cells, modified to target a protein called DLL3 on cancer cells. The trial aims to find the safest dose and check if the treatment shrinks tumors. About 80 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.